In the HERACLES-A trial, 33 KRAS exon 2 WT, HER-2 positive metastatic colorectal cancer patients were treated with a combination of lapatinib and trastuzumab, achieving an overall response rate of 30%, with two complete responders [135]. Here, ERBB2 is linked to metastatic colorectal cancer.